a biotech company with a mission to accelerate humanity’s transition to the "age of immunity", we are the business busily decoding the human immune system.
Company profile
Ticker
ADTX
Exchange
Website
CEO
Amro Albanna
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Aditx Therapeutics, Inc., ADiTx Therapeutics, Inc.
SEC CIK
Corporate docs
IRS number
823204328
ADTX stock data
Latest filings (excl ownership)
10-K
2023 FY
Annual report
16 Apr 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
12 Apr 24
8-K
Entry into a Material Definitive Agreement
4 Apr 24
NT 10-K
Notice of late annual filing
1 Apr 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
11 Mar 24
425
Business combination disclosure
4 Mar 24
8-K
Entry into a Material Definitive Agreement
4 Mar 24
8-K
Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
1 Mar 24
8-K
Entry into a Material Definitive Agreement
29 Feb 24
8-K/A
Financial Statements and Exhibits
22 Feb 24
Latest ownership filings
SC 13G/A
CVI Investments, Inc.
14 Feb 24
SC 13G/A
INTRACOASTAL CAPITAL, LLC
6 Feb 24
SC 13G/A
SABBY MANAGEMENT, LLC
2 Jan 24
4
Jeffrey W. Runge
13 Nov 23
4
Charles Athle Nelson
13 Nov 23
4
Rowena Albanna
13 Nov 23
4
Amro A. Albanna
13 Nov 23
4
Corinne Pankovcin
13 Nov 23
4
Thomas J Farley
13 Nov 23
4
Brian Michael Brady
13 Nov 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.65 mm | 1.65 mm | 1.65 mm | 1.65 mm | 1.65 mm | 1.65 mm |
Cash burn (monthly) | (no burn) | 632.79 k | 3.25 mm | 2.47 mm | 2.68 mm | 1.83 mm |
Cash used (since last report) | n/a | 4.23 mm | 21.72 mm | 16.50 mm | 17.90 mm | 12.25 mm |
Cash remaining | n/a | -2.58 mm | -20.06 mm | -14.84 mm | -16.25 mm | -10.60 mm |
Runway (months of cash) | n/a | -4.1 | -6.2 | -6.0 | -6.1 | -5.8 |
Institutional ownership, Q3 2023
32.6% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 13 |
Opened positions | 4 |
Closed positions | 6 |
Increased positions | 0 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 825.97 mm |
Total shares | 542.88 k |
Total puts | 0.00 |
Total calls | 37.80 k |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
CVI Investments | 476.76 k | $0.00 |
Schonfeld Strategic Advisors | 33.90 k | $423.41 mm |
Armistice Capital | 28.00 k | $349.72 mm |
Tower Research Capital | 1.88 k | $23.51 mm |
Qube Research & Technologies | 1.20 k | $14.99 mm |
UBS UBS Group AG - Registered Shares | 809.00 | $10.10 mm |
Natixis | 250.00 | $3.28 mm |
MS Morgan Stanley | 37.00 | $462.00 k |
IFP Advisors | 28.00 | $349.00 k |
Advisor | 11.00 | $136.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
8 Nov 23 | Charles Athle Nelson | Options Common Stock | Grant | Acquire A | No | No | 5.01 | 470 | 2.35 k | 470 |
8 Nov 23 | Brian Michael Brady | Options Common Stock | Grant | Acquire A | No | No | 5.01 | 470 | 2.35 k | 470 |
8 Nov 23 | Thomas J Farley | Options Common Stock | Grant | Acquire A | No | No | 5.01 | 4,702 | 23.56 k | 4,702 |
8 Nov 23 | Runge Jeffrey W. | Options Common Stock | Grant | Acquire A | No | No | 5.01 | 470 | 2.35 k | 470 |
8 Nov 23 | Rowena Albanna | Options Common Stock | Grant | Acquire A | No | No | 5.01 | 4,702 | 23.56 k | 4,702 |
News
Why Stryve Foods Shares Are Trading Lower By Around 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
2 Apr 24
Why Aditxt Stock Is Volatile Today
2 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 Apr 24
Aditxt, Through Adivir Subsidiary, To Acquire All Issued And Outstanding Class A Common Shares Of Appili; Appili Shareholders To Receive 0.002745004 Shares Of Aditxt And $0.0467 For Each Appili Share Held, Representing Total Consideration Of ~$0.0561
2 Apr 24
Press releases
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
2 Apr 24
Appili Therapeutics Signs Definitive Agreement to be Acquired by Aditxt, Inc.
2 Apr 24
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
27 Mar 24
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
20 Mar 24
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
7 Mar 24